



## Introduced the $^{68}\text{Ge}/^{68}\text{Ga}$ generator with highest produced $^{68}\text{Ga}$ activity Gholamhosseini-Nazari M<sup>1\*</sup>, Ali Rahiminezhad

<sup>1</sup> Pars Isotope company, P.O.BOX:17376-63181, Tehran, Iran

\* Email: mgh.nazari2@gmail.com

### Abstract

Interest in using  $^{68}\text{Ga}$  is rapidly increasing for clinical PET applications due to its favorable imaging characteristics and increased accessibility. Focus of this present was to provide our evaluation of the  $\text{TiO}_2\text{-SnO}_2$ -based  $^{68}\text{Ge}/^{68}\text{Ga}$  generator. The introduced generator has highest  $^{68}\text{Ga}$  activity compared to other commercial  $^{68}\text{Ge}/^{68}\text{Ga}$  generators.

This generator from Pars Isotope company with a nominal activity of 70 mCi showed a stable  $^{68}\text{Ga}$  elution profile. The obtained results will be useful in standardizing the evaluation of  $^{68}\text{Ge}/^{68}\text{Ga}$  generator for clinical use.

**Keywords:**  $^{68}\text{Ga}/^{68}\text{Ga}$  generator,  $^{68}\text{Ga}$ , Gallium-68, PARS-GalluGEN

### Introduction

$^{68}\text{Ga}$  ( $^{68}\text{Ga}$ ) is one of the radionuclides that is widely used for diagnostic purposes in Nuclear Medicine. In contrast to the more frequently used PET nuclides  $^{18}\text{F}$  or  $^{11}\text{C}$ , there is no need for an on-site cyclotron. At the same time, more detailed good manufacturing practice (GMP) standards for production of radiopharmaceuticals in Europe call for robust and reproducible production routines for  $^{68}\text{Ga}$  radiopharmaceuticals [1].

The  $^{68}\text{Ge}/^{68}\text{Ga}$  generator has emerged as a convenient source to provide  $^{68}\text{Ga}$  in a hospital radiopharmacy for the synthesis of  $^{68}\text{Ga}$ -labeled radiopharmaceuticals and represents a developmental milestone in the field of PET-based molecular imaging. As a metallic radionuclide,  $^{68}\text{Ga}$  has great capability to be used for radiolabeling molecular tumor targeting vectors, such as peptides or proteins (monoclonal antibodies or fragments thereof), through a bifunctional chelator link [2,3]. Over the years, a variety of  $^{68}\text{Ge}/^{68}\text{Ga}$  generators have been developed using a gamut of sorbents such as  $\text{Al}_2\text{O}_3$ ,  $\text{CeO}_2$ ,  $\text{SnO}_2$ ,  $\text{TiO}_2$ ,  $\text{ZrO}_2$ , and organic matrices [1].

Common commercially available generators are Cyclotron Co. Ltd. (Obninsk, Russian Federation;  $\text{TiO}_2$ -based), Eckert & Ziegler GalliaPharm (Germany;  $\text{TiO}_2$ -based), iThemba LABORATORIES (Republic of South Africa;  $\text{SnO}_2$ -based), ITG Isotope Technologies Garching GmbH (Munich, Germany; silicabased), Galli Eo (from IRE EliT, Fleurus, Belgium; unspecified resin) and PARS Isotope PARS-GalluGEN (Tehran, Iran;  $\text{SnO}_2/\text{TiO}_2$  based) [4].

To date, the commercially available  $^{68}\text{Ge}/^{68}\text{Ga}$  generators do not exceed the capacity of 1.85 GBq (50 mCi) and recently itG produced new  $^{68}\text{Ge}/^{68}\text{Ga}$  generator with a nominal activity of 4.04 GBq (109 mCi) and elution efficiency about 60% [4].

In this context, we report the new  $^{68}\text{Ge}/^{68}\text{Ga}$  generator of PARS Isotope as PARS-GalluGEN (Fig 1) which nominally provided 70 mCi  $^{68}\text{Ga}$  (120 mCi loaded  $^{68}\text{Ge}$ ). The eluted  $^{68}\text{Ga}$  have low metallic impurities and exhibited low  $^{68}\text{Ge}$  breakthrough and suitability of the  $^{68}\text{Ga}$  for the preparation of  $^{68}\text{Ga}$ -labeled radiotracers.



Figure 1. 70 mCi  $^{68}\text{Ge}/^{68}\text{Ga}$  generator

### Experimental

#### Preparation of the materials

PARS-GalluGEN generator eluted with 3 mL of 0.1 M HCl a flow rate of 3 mL/min. The generator elution profiles were studied by collecting the eluates from different generators as 0.5 mL aliquots, and the activity of each fraction was determined by measuring the activity in a dose calibrator.



After an elution of the PARS–GalluGEN generator the <sup>68</sup>Ga will be built up by the continuous decay of the parent <sup>68</sup>Ge. The generator requires at least 7 hours to achieve almost full yield after being eluted, but in practice it is also possible to elute the generator after 4 hours. The output will decrease due to decay of the <sup>68</sup>Ge parent over time. For example, after 9 months' decay (39 weeks), the <sup>68</sup>Ge will be reduced by 50 %.

The breakthrough refers to the actual <sup>68</sup>Ge content of the eluate, and is reported as the <sup>68</sup>Ge activity in the eluate relative to that on the generator column. The European Pharmacopoeia 8 specifies that gallium (<sup>68</sup>Ga) chloride solution shall not contain more than 10 µg of Fe and Zn per GBq of <sup>68</sup>Ga in eluate that is used for radiolabelling and that no more than 0.001% of <sup>68</sup>Ge should be present in the <sup>68</sup>Ga eluate. Each generator was eluted at least once in a day and the elution yield was determined using the following equation:

$$\text{Elution yield}(\%) = \frac{As(t)}{A_1^0(1 - e^{-\lambda_1 t})} \times 100$$

### Results and discussion

The most commonly available commercial <sup>68</sup>Ge/<sup>68</sup>Ga generator systems are based on TiO<sub>2</sub> or SnO<sub>2</sub> as sorbents, from which ionic <sup>68</sup>Ga<sup>3+</sup> is eluted in 0.1–1M HCl. Comparison of these data and our experimental lead us to choose the mixed resin as sorbent [5].

A small amount of <sup>68</sup>Ge is eluted from the column with each elution. <sup>68</sup>Ge breakthrough is expressed as a percentage of total <sup>68</sup>Ge eluted from the column to loaded <sup>68</sup>Ge with decay correction factor. The <sup>68</sup>Ge

	<sup>68</sup> Ge	<sup>68</sup> Ga
Half-live	270.95 days	67.71 minutes
Type of decay	Electron capture	Positron emission
X-rays	9.225 (13.1 %) 9.252 (25.7 %) 10.26 (1.64 %) 10.264 (3.2 %) 10.366 (0.03 %)	8.616 (1.37 %) 8.639 (2.69 %) 9.57 (0.55 %)
gammas		511 keV (178.28 %), 578.55 keV (0.03 %) 805.83 keV (0.09 %), 1077.34 keV (3.22 %) 1260.97 keV (0.09 %) 1883.16 keV (0.14 %)
beta+		Energy max. Energy 352.60 keV 821.71 keV (1.20 %) 836.00 keV 1899.01 keV (87.94 %)

breakthrough for this generator is not more than 0.001 % of the eluted <sup>68</sup>Ge activity and typically begins as low as 0.0005 % at the point of release and may rise slightly with the number of elution.

Table 1: Physical characteristics of mother and daughter

All development batches were produced using drug substance Gallium Chloride (<sup>68</sup>GaCl<sub>3</sub>) obtain by decay of adsorbed <sup>68</sup>Ge on tin dioxide and titanium dioxide column physical and chemical test were performed to characterize the radionuclide. Physical characteristics of both mother and daughter are summarized in Table 1.

### Conclusions

PARS-GalluGEN Generators are delivered with a given amount of elutable <sup>68</sup>Ga activity at calibration time and eluted with 0.1 M HCl and solution suitable for the subsequent labelling.. Elution yield with 3 ml of 0.1 M HCl is 62-52% of the loaded <sup>68</sup>Ge on the column. Elution profile of the generator show that more than 90% of the elutable activity is collected in the middle 2ml of the eluate. Only a low percentage of activity (< 10%) was eluted in the first and final 0.5 mL fractions

### Acknowledgments

The corresponding author is grateful to Doctor Khosro Ardaneh for providing valuable suggestions.

### References

- [1] L. M. Pecora, T. L. Carroll, G. A. Johnson, *Investigation of Cut Control Equations in the Gas Centrifuge Cascades*, J.Appl. Phys. 20, 2221 (1998)
- [2] J.M. Gonzalez-Leal, P. Krecmer, J. Prokop and S.R. Elliot, in: *Photo-Induced Metastability in Amorphous Semiconductors*, edited by A.V. Kolobov (Wiley-VCH, Weinheim, 2003), pp. 338-340.
- [1] H. J. Wester. GMP production. Shaping the future. *Nuklearmedizin. Nuclear medicine*, 51, N1, (2012)
- [2] F. Roßsch. <sup>68</sup>Ge/<sup>68</sup>Ga generators: Past, present, and future. *Recent Results Cancer Res.* 3, 194, (2013)
- [3] Roesch F, Riss PJ. The renaissance of the <sup>68</sup>Ge/<sup>68</sup>Ga radionuclide generator initiates new developments in <sup>68</sup>Ga radiopharmaceutical chemistry. *Curr Top Med Chem*,10, 1633, (2010)
- [4] N. N. Waterhouse, A. Amor-Coarasa, A. Nikolopol, & , J. W. Babich. Otto: a 4.04 GBq (109 mCi) <sup>68</sup>Ge/<sup>68</sup>Ga generator, first of its kind-extended quality control and performance evaluation in the clinical production of [<sup>68</sup>Ga] Ga-PSMA-11. *EJNMMI radiopharmacy and chemistry*, 5, (2020).
- [5] I, Velikyan, <sup>68</sup>Ga-based radiopharmaceuticals: production and application relationship. *Molecules*, 20, 12913, (2015).



**1<sup>st</sup> International & 28<sup>th</sup> National Conference  
on Nuclear Science & Technology 2022 (ICNST22)**



Nuclear Science & Technology  
Research Institute